Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
NCT02309177
Completed
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2019
Locations: UC Davis Cancer Center, Sacramento, California +14 locations
Conditions: Breast Neoplasms, Pancreatic Neoplasms
Register for Updates
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
NCT00003644
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to c... Read More
Gender:
FEMALE
Ages:
120 years and below
Trial Updated:
05/23/2019
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +150 locations
Conditions: Ovarian Cancer
Register for Updates
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00234052
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help ki... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/23/2019
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois +4 locations
Conditions: Lung Cancer
Register for Updates
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
NCT01263782
Completed
The goal of this clinical research study is to learn if knowing biomarker status can help researchers find better treatment combinations for patients with advanced NSCLC. Researchers want to use biomarker status to decide what drug (bevacizumab, or cixutumumab) to give in combination with carboplatin and pemetrexed. The safety of these drug combinations will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
NCT01664754
Completed
This phase I trial studies the side effects and best dose of exemestane in combination with pemetrexed disodium and carboplatin in treating post-menopausal women with stage IV non-small cell lung cancer. Exemestane may stop the growth of tumor calls by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/03/2019
Locations: Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Stage IV Non-small Cell Lung Cancer
Register for Updates
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
NCT02592876
Terminated
The purpose of this randomized, open-label study is to evaluate the safety and efficacy of denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when compared to RICE alone in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma. Eligible patients must also be candidates for autologous stem cell transplant. Patients will be randomly assigned in a 1:1 ratio to receive 3 cycles of study treatment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2019
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +28 locations
Conditions: Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b, Follicular Lymphoma, Grade 3b
Register for Updates
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
NCT03386838
Withdrawn
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first diagnosed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2019
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003194
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have recurrent or refractory solid tumors.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
04/03/2019
Locations: Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington +1 locations
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00011986
Completed
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/03/2019
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Register for Updates
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
NCT01490749
Completed
The purpose of this study is to test the drug RAD001 in combination with another chemotherapy drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination. The standard of care for patients who have esophageal cancer that has not moved to other areas of the body (non-metastatic) includes a combination of chemotherapy, radiation therapy and possi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2019
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Esophageal Cancer, Neoplasms, Esophageal
Register for Updates
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
NCT01715233
Completed
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2019
Locations: SKCCC at Johns Hopkins, Baltimore, Maryland
Conditions: Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
Register for Updates
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00459121
Terminated
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vandetanib together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE:... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/13/2019
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Lung Cancer
Register for Updates